| First Author | Hwang S | Year | 2023 |
| Journal | Int J Mol Sci | Volume | 24 |
| Issue | 16 | PubMed ID | 37628783 |
| Mgi Jnum | J:339625 | Mgi Id | MGI:7523451 |
| Doi | 10.3390/ijms241612602 | Citation | Hwang S, et al. (2023) KLF10 Inhibits TGF-beta-Mediated Activation of Hepatic Stellate Cells via Suppression of ATF3 Expression. Int J Mol Sci 24(16) |
| abstractText | Liver fibrosis is a progressive and debilitating condition characterized by the excessive deposition of extracellular matrix proteins. Stellate cell activation, a major contributor to fibrogenesis, is influenced by Transforming growth factor (TGF-beta)/SMAD signaling. Although Kruppel-like-factor (KLF) 10 is an early TGF-beta-inducible gene, its specific role in hepatic stellate cell activation remains unclear. Our previous study demonstrated that KLF10 knockout mice develop severe liver fibrosis when fed a high-sucrose diet. Based on these findings, we aimed to identify potential target molecules involved in liver fibrosis and investigate the mechanisms underlying the KLF10 modulation of hepatic stellate cell activation. By RNA sequencing analysis of liver tissues from KLF10 knockout mice with severe liver fibrosis induced by a high-sucrose diet, we identified ATF3 as a potential target gene regulated by KLF10. In LX-2 cells, an immortalized human hepatic stellate cell line, KLF10 expression was induced early after TGF-beta treatment, whereas ATF3 expression showed delayed induction. KLF10 knockdown in LX-2 cells enhanced TGF-beta-mediated activation, as evidenced by elevated fibrogenic protein levels. Further mechanistic studies revealed that KLF10 knockdown promoted TGF-beta signaling and upregulated ATF3 expression. Conversely, KLF10 overexpression suppressed TGF-beta-mediated activation and downregulated ATF3 expression. Furthermore, treatment with the chemical chaperone 4-PBA attenuated siKLF10-mediated upregulation of ATF3 and fibrogenic responses in TGF-beta-treated LX-2 cells. Collectively, our findings suggest that KLF10 acts as a negative regulator of the TGF-beta signaling pathway, exerting suppressive effects on hepatic stellate cell activation and fibrogenesis through modulation of ATF3 expression. These results highlight the potential therapeutic implications of targeting the KLF10-ATF3 axis in liver fibrosis treatment. |
